We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets.
View Top Employees from Principia BiopharmaWebsite | http://www.principiabio.com |
Ticker | PRNB |
Revenue | $34 million |
Funding | $423.3 million |
Employees | 25 (25 on RocketReach) |
Founded | 2008 |
Address | 220 E Grand Ave, South San Francisco, California 94080, US |
Phone | (650) 416-7700 |
Technologies |
JavaScript,
HTML,
PHP
+37 more
(view full list)
|
Industry | Biotechnology, Drug Manufacturing & Research, Biopharma, Pharmaceuticals, Healthcare, Health Care, Science and Engineering, Life Science |
Web Rank | 6 Million |
Keywords | Principia Biopharma, Principia Biopharma Inc., Principiabio, Principia Pharmaceutical Corp, Principia Biopharam |
Competitors | Concert Pharmaceuticals, Inc., Karus Therapeutics Limited, Mimetogen Pharmaceuticals Inc., Pharmacyclics, an AbbVie Company, Welichem Biotech Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Principia Biopharma employee's phone or email?
The Principia Biopharma annual revenue was $34 million in 2024.
Wei Chen is the Senior Director, Analytical Development of Principia Biopharma.
25 people are employed at Principia Biopharma.
Principia Biopharma is based in South San Francisco, California.
The NAICS codes for Principia Biopharma are [32, 32541, 3254, 325].
The SIC codes for Principia Biopharma are [28, 283].